Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
PROCEPT BioRobotics Corporation
PRCT
NASDAQ·Healthcare·Medical - Devices·Mkt cap $1.3B
$21.03
▼ -10.40%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$19.35 - $62.17
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 59.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary image-guided robotic platform with aquablation technology
- Focused specialization in urology with deep clinical expertise
- Growing installed base and expanding surgeon adoption network
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Rising BPH prevalence in aging male population
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Weak
-6.6% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PRCT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 22, 2026
APR 29, 2026
Reported EPS of -$0.56 vs -$0.55 consensus (-1.8% surprise). Revenue of $83.1M vs $80.5M expected (+3.2%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-1.8%
Next: Apr 22, 2026
Revenue trend · last 8Q
—
—
+57%
+55%
+48%
+43%
+12%
+20%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$53.4M
$58.4M
$68.2M
$69.2M
$79.2M
$83.3M
$76.4M
$83.1M
Margins · last 8Q
Gross
—
Operating
—
Profit
-38.1%
Wall Street consensus
9 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
22%
Sell
11%
Median Price Target
$35.00
▲ +66.4% vs $21.03
Latest: Citi · Jul 2, 2026
1 analyst covering